Literature DB >> 18553389

Dopamine transporter polymorphism modulates oculomotor function and DAT1 mRNA expression in schizophrenia.

Ikwunga Wonodi1, L Elliot Hong, O Colin Stine, Braxton D Mitchell, Amie Elliott, Rosalinda C Roberts, Robert R Conley, Robert P McMahon, Gunvant K Thaker.   

Abstract

Smooth pursuit eye movement (SPEM) deficit is an established schizophrenia endophenotype with a similar neurocognitive construct to working memory. Frontal eye field (FEF) neurons controlling SPEM maintain firing when visual sensory information is removed, and their firing rates directly correlate with SPEM velocity. We previously demonstrated a paradoxical association between a functional polymorphism of dopamine signaling (COMT gene) and SPEM. Recent evidence implicates the dopamine transporter gene (DAT1) in modulating cortical dopamine and associated neurocognitive functions. We hypothesized that DAT1 10/10 genotype, which reduces dopamine transporter expression and increases extracellular dopamine, would affect SPEM. We examined the effects of DAT1 genotype on: Clinical diagnosis in the study sample (n = 418; 190 with schizophrenia), SPEM measures in a subgroup with completed oculomotor measures (n = 200; 87 schizophrenia), and DAT1 gene expression in FEF tissue obtained from postmortem brain samples (n = 32; 16 schizophrenia). DAT1 genotype was not associated with schizophrenia. DAT1 10/10 genotype was associated with better SPEM in healthy controls, intermediate SPEM in unaffected first-degree relatives of schizophrenia subjects, and worse SPEM in schizophrenia subjects. In the gene expression study, DAT1 10/10 genotype was associated with significantly reduced DAT1 mRNA transcript in FEF tissue from healthy control donors (P < 0.05), but higher expression in schizophrenia donors. Findings suggest regulatory effects of another gene(s) or etiological factor in schizophrenia, which modulate DAT1 gene function. 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18553389      PMCID: PMC2774755          DOI: 10.1002/ajmg.b.30811

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  44 in total

Review 1.  The 3' untranslated region of messenger RNA: A molecular 'hotspot' for pathology?

Authors:  B Conne; A Stutz; J D Vassalli
Journal:  Nat Med       Date:  2000-06       Impact factor: 53.440

2.  Functional neuroanatomy of smooth pursuit and predictive saccades.

Authors:  G A O'Driscoll; A L Wolff; C Benkelfat; P S Florencio; S Lal; A C Evans
Journal:  Neuroreport       Date:  2000-04-27       Impact factor: 1.837

Review 3.  Eye movement dysfunction in schizophrenia: a heritable characteristic for enhancing phenotype definition.

Authors:  M E Calkins; W G Iacono
Journal:  Am J Med Genet       Date:  2000

4.  Poor performance in smooth pursuit and antisaccadic eye-movement tasks in healthy siblings of patients with schizophrenia.

Authors:  B Karoumi; M Saoud; T d'Amato; F Rosenfeld; P Denise; C Gutknecht; V Gaveau; F E Beaulieu; J Daléry; T Rochet
Journal:  Psychiatry Res       Date:  2001-04-15       Impact factor: 3.222

Review 5.  Recasting the smooth pursuit eye movement system.

Authors:  Richard J Krauzlis
Journal:  J Neurophysiol       Date:  2004-02       Impact factor: 2.714

6.  Cortical networks subserving pursuit and saccadic eye movements in humans: an FMRI study.

Authors:  R A Berman; C L Colby; C R Genovese; J T Voyvodic; B Luna; K R Thulborn; J A Sweeney
Journal:  Hum Brain Mapp       Date:  1999       Impact factor: 5.038

Review 7.  Eye movements and the search for the essence of schizophrenia.

Authors:  P S Holzman
Journal:  Brain Res Brain Res Rev       Date:  2000-03

8.  Prediction of dopamine transporter binding availability by genotype: a preliminary report.

Authors:  L K Jacobsen; J K Staley; S S Zoghbi; J P Seibyl; T R Kosten; R B Innis; J Gelernter
Journal:  Am J Psychiatry       Date:  2000-10       Impact factor: 18.112

9.  The human dopamine transporter gene: the 5'-flanking region reveals five diallelic polymorphic sites in a Caucasian population sample.

Authors:  C Rubie; F Schmidt; M Knapp; J Sprandel; C Wiegand; J Meyer; G Jungkunz; P Riederer; G Stöber
Journal:  Neurosci Lett       Date:  2001-01-12       Impact factor: 3.046

10.  Heroin abuse is characterized by discrete mesolimbic dopamine and opioid abnormalities and exaggerated nuclear receptor-related 1 transcriptional decline with age.

Authors:  Monika Cs Horvath; Gabor G Kovacs; Viktor Kovari; Katalin Majtenyi; Yasmin L Hurd; Eva Keller
Journal:  J Neurosci       Date:  2007-12-05       Impact factor: 6.167

View more
  17 in total

1.  Association of variants in DRD2 and GRM3 with motor and cognitive function in first-episode psychosis.

Authors:  Rebekka Lencer; Jeffrey R Bishop; Margret S H Harris; James L Reilly; Shitalben Patel; Rick Kittles; Konasale M Prasad; Vishwajit L Nimgaonkar; Matcheri S Keshavan; John A Sweeney
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-10-25       Impact factor: 5.270

2.  Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes.

Authors:  Ikwunga Wonodi; O Colin Stine; Korrapati V Sathyasaikumar; Rosalinda C Roberts; Braxton D Mitchell; L Elliot Hong; Yasushi Kajii; Gunvant K Thaker; Robert Schwarcz
Journal:  Arch Gen Psychiatry       Date:  2011-07

3.  A Meta-analysis of the Association Between SLC6A3 Gene Polymorphisms and Schizophrenia.

Authors:  Feng-Ling Xu; Mei Ding; Xue Wu; Yong-Ping Liu; Xi Xia; Jun Yao; Bao-Jie Wang
Journal:  J Mol Neurosci       Date:  2019-08-22       Impact factor: 3.444

Review 4.  Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia.

Authors:  Ikwunga Wonodi; Robert Schwarcz
Journal:  Schizophr Bull       Date:  2010-02-10       Impact factor: 9.306

5.  Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophrenia.

Authors:  Ikwunga Wonodi; Robert P McMahon; Nithin Krishna; Braxton D Mitchell; Judy Liu; Matthew Glassman; L Elliot Hong; James M Gold
Journal:  Schizophr Res       Date:  2014-11-14       Impact factor: 4.939

Review 6.  Psychopathological aspects of dopaminergic gene polymorphisms in adolescence and young adulthood.

Authors:  Zsofia Nemoda; Anna Szekely; Maria Sasvari-Szekely
Journal:  Neurosci Biobehav Rev       Date:  2011-04-15       Impact factor: 8.989

7.  Association between dopaminergic polymorphisms and borderline personality traits among at-risk young adults and psychiatric inpatients.

Authors:  Zsofia Nemoda; Karlen Lyons-Ruth; Anna Szekely; Eszter Bertha; Gabor Faludi; Maria Sasvari-Szekely
Journal:  Behav Brain Funct       Date:  2010-01-12       Impact factor: 3.759

8.  Genomic features of the human dopamine transporter gene and its potential epigenetic States: implications for phenotypic diversity.

Authors:  Elena Shumay; Joanna S Fowler; Nora D Volkow
Journal:  PLoS One       Date:  2010-06-10       Impact factor: 3.240

9.  Neuregulin-1 genotypes and eye movements in schizophrenia.

Authors:  H Magnus Haraldsson; Ulrich Ettinger; Brynja B Magnusdottir; Andres Ingason; Samuel B Hutton; Thordur Sigmundsson; Engilbert Sigurdsson; Hannes Petursson
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-03       Impact factor: 5.270

10.  Methylphenidate effects on brain activity as a function of SLC6A3 genotype and striatal dopamine transporter availability.

Authors:  Anna-Maria Kasparbauer; Dan Rujescu; Michael Riedel; Oliver Pogarell; Anna Costa; Thomas Meindl; Christian la Fougère; Ulrich Ettinger
Journal:  Neuropsychopharmacology       Date:  2014-09-15       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.